[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

633A.O2.6 Myelodysplastic Syndromes: Molecular Pathogenesis

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 6, 2010: 2:45 PM-4:15 PM
Valencia D (Orange County Convention Center)
Moderators:
Peter Aplan, MD, NIH and Eva Hellström-Lindberg, Karolinska Institutet
2:45 PM
Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies

Hideki Makishima, MD, PhD1, Ania Jankowska, MSC1*, Ramon V. Tiu, MD2, Hadrian Szpurka, PhD, MSC1, Yuka Sugimoto, MD, PhD1, Quteba Ebrahem, MD1*, Zhenbo Hu, MD3, Reda Z Mahfouz, MD1, Yogen Saunthararajah, MD4, Kathryn Guinta1*, Mehdi Keddache, MSC5*, Christine L. O'Keefe, PhD1, Mikkael A. Sekeres, MD, MS4, Alan F. List6, Michael A McDevitt, MD, PhD7 and Jaroslaw P. Maciejewski, MD, PhD1

1Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
2Departments of Translational Hematology and Oncolgy Research and Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH
3Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH
5Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
6H. Lee Moffitt Cancer Center, Tampa, FL
7Department of Oncology, Division of Hematological Malignancy, Johns Hopkins University School of Medicine, Baltimore, MD

3:00 PM
Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome

Matthew J. Walter1, Dong Shen2*, Jin Shao1*, Li Ding2*, Marcus Grillot1*, Michael McLellan2*, Robert Fulton2*, Heather Schmidt2*, Joelle Kalicki-Veizer2*, Michelle O'Laughlin2*, Peter Westervelt1*, John F. DiPersio1, Elaine R Mardis2*, Richard Wilson2*, Timothy J Ley3 and Timothy Graubert1

1Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO
2The Genome Center, Washington University, St. Louis, MO
3Department of Medicine, Siteman Cancer Center, The Genome Center, Washington University School of Medicine, St. Louis, MO

3:15 PM
Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 In MDS CD34+ Hematoprogenitor Cells

Yue Wei, PhD1, George Calin, MD PhD2*, Yu Jia3*, Hong Zheng3*, Sara McCay3*, Hui Yang, MD, PhD3*, Zhihong Fang1* and Guillermo Garcia-Manero, MD3

1Leukemia, MD Anderson Cancer Center, Houston, TX
2Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX
3Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

3:30 PM
Dissecting the Mechanism of Apoptosis and Leukemic Transformation In Myelodysplasia

Christopher I Slape1, Jesslyn Saw1*, Laura M Failla1*, Peter D Aplan2*, Stephen M Jane1 and David J Curtis1*

1Bone Marrow Research Laboratories, Royal Melbourne Hospital, Parkville, Australia
2NIH, Bethesda

3:45 PM
Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2

Anna Jankowska, MSc1*, Hideki Makishima, MD, PhD2, Ramon V. Tiu, MD3, Hadrian Szpurka, PhD, MSc1, Yun Huang (equal contribution)4*, Yuka Sugimoto, MD, PhD1, Courtney Prince, BS1*, Christine L. O'Keefe, PhD2, Eric Hsi, MD5, Alan F. List6, Mikkael A. Sekeres, MD, MS7, Anjana Rao, PhD4*, Michael A McDevitt, MD, PhD8 and Jaroslaw P Maciejewski, MD, PhD, FACP1

1Translational Hematology and Oncology Research, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
2Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
4Department of Pathology, Harvard Medical School, Immune Disease Institute and Program in Cellular and Molecular Medicine, Boston, MA
5Clinical Pathology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
6H. Lee Moffitt Cancer Center, Tampa, FL
7Cleveland Clinic, Taussig Cancer Center, Cleveland, OH
8Department of Oncology, Division of Hematological Malignancy, Johns Hopkins University School of Medicine, Baltimore

4:00 PM
Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype

Kathy L. McGraw1*, Lan Min Zhang, MD2*, Dana E. Rollison, PhD3, Hui-Yi Lin, PhD2*, Bhupendra Rawal, MS2*, Debbie Billingsley, RN-BSN4*, Sandra E. Kurtin, RN, MS, ANP5, Gisela Caceres, Ph.D.2*, Justine Clark, MS2*, Lubomir Sokol, MD, PhD2, P.K. Epling-Burnette, PharmD, PhD2, Kathryn Guinta6*, Jaroslaw P. Maciejewski, MD, PhD6, Mar Mallo7*, Francesc Solé, PhD8, Maria Jose Calasanz, PhD9*, Jose Cervera, MD10*, Esperanzo Such11*, Teresa Gonzalez Martinez12*, Sandy Sung13*, Thomas J. Nevill, MD, FRCPC14, Aly Karsan, MD, FRCPC13 and Alan F. List2

1H. Lee Moffitt Cancer Center and Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL
2H. Lee Moffitt Cancer Center, Tampa, FL
3Division of Cancer Prevention and controls, Moffitt Cancer Center, Tampa, FL
4H. Lee Moffitt Cancer Center & Research Institute, H. Lee Moffitt Cancer Center, Tampa, FL
5Arizona Cancer Center, Tucson, AZ
6Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
7IMIM-Hospital del Mar, Barcelona
8Patologia, LaB. Citogenetica, Barcelona, Spain
9Genetics, University of Navarra, Pamplona, Spain
10Hematology Department, University Hospital La Fe, Valencia, Spain
11Hematology, University Hospital La Fe, Valencia, Spain
12Fundacion Publica de Medicina Xenomica, Spain
13British Columbia Cancer Research Centre, Vancouver, BC, Canada
14Leukemia/BMT Program of BC, British Columbia Cancer Agency, Vancouver, BC, Canada

*signifies non-member of ASH